Amado said Zai anticipates a potential accelerated approval submission in 2027 and “a first global approval in 2028.” He also pointed to clinical activity in patients with brain metastases, including an 80% objective response rate in 10 patients with untreated brain metastases, and said the company plans to present additional data in coming months.President and Head of Global R&D Dr. Rafael Amado detailed progress for zoci (a DLL3-targeting antibody-drug conjugate), which the company is advancing in small c ...

I think that um right now we are at a decisionmaking point and very close to a recession and I'm worried about something worse than a recession if this isn't handled well. A recession is two negative quarters of GDP and whether it goes slightly there. We always have those things. We have something that's much more profound. We have a breaking down of the monetary order. we are going to change the monetary order because we cannot spend the amounts of money. So we have that problem and when we talk about the ...